Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease

被引:8
|
作者
Villanueva, Fernando N.
Antonio Perez-Simon, Jose [1 ]
Silva, Fernando F.
Caballero-Velazquez, Teresa T.
Sanchez-Guijo, Fermin F.
Canizo, Conzuelo C.
Vazquez, Lourdes L.
Caballero, Dolores D.
San Miguel, Jesus F.
机构
[1] Hosp Clin Univ, Serv Hematol, Salamanca 37007, Spain
关键词
Gastrointestinal chronic graft-versus-hot disease; cGVHD; Beclomethasone dipropionate; BDP; Allogeneic stem cell transplantation; CONSENSUS DEVELOPMENT PROJECT; WORKING GROUP-REPORT; HEMATOPOIETIC-CELL TRANSPLANTATION; CLINICAL-TRIALS; MARROW TRANSPLANTATION; RANDOMIZED-TRIAL; PREDNISONE; DIAGNOSIS; SURVIVAL; LEUKEMIA;
D O I
10.1016/j.bbmt.2009.05.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The most common approach for the treatment of chronic graft-versus-host disease (cGVHD) has been the long-term use of systemic steroids. Beclomethasone dipropionate (BDP) is a topically active corticosteroid with relatively low absorption from the gastrointestinal mucosa. It has been successfully used to treat acute GVHD (aGVHD), but its use in the cGVHD setting is far more limited. In the current study, BDP was administered to 33 patients who underwent allogeneic transplantation and had biopsy-proven gastrointestinal cGVHD (GI cGVHD). Twenty-six patients with GI cGVHD received BDP as first-line and 7 as either second-or third-line treatment. All patients received BDP together with a calcineurin inhibitor, except for I patient who was also receiving mycophenolate mofetil (MMF). BDP was administered for a minimum of 16 weeks and was tapered during 4 additional weeks. Of those patients receiving BDP as the first line of treatment, 22 (84.6%) achieved complete remission (CR) of GI cGVHD, 2 (7.7%) achieved a partial response (PR) and 2 (7.7%) did not respond or progressed. Median time to response was 28 days. Nevertheless, only 7 (27%) patients had maintained the response at last follow-up, whereas 19 (73%) finally relapsed or progressed. Median time to relapse was 147 days after the end of BDP. In the case of the patients who received BDP as a second-or third-line treatment, 3 (42.9%) achieved CR and 2 (28.6%) PR. For the whole series of patients, 13 patients (39.4%) were not receiving immunosuppressive treatment at final follow-up. Only 4 patients developed cytomegalovirus (CMV) reactivation, which was successfully treated with antiviral drugs. No fungal infection was observed during the treatment period. In conclusion, the current study shows that BDP, in the absence of systemic steroids, is a highly effective initial therapeutic approach for GI cGVHD, which helps to avoid complications related to systemic steroids.
引用
收藏
页码:1331 / 1336
页数:6
相关论文
共 50 条
  • [1] Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD)
    Castilla, C.
    Perez-Simon, J. A.
    Sanchez-Guijo, F. M.
    Diez-Campelo, M.
    Ocio, E.
    Perez-Persona, E.
    Lopez-Villar, O.
    Vazquez, L.
    Caballero, D.
    San Miguel, J. F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (09) : 936 - 941
  • [2] Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal Graft-versus-Host disease
    Iyer, RV
    Hahn, T
    Roy, HN
    Battiwalla, M
    Cooper, M
    Anderson, B
    Paplham, P
    Brown, K
    Bambach, B
    Segal, BH
    McCarthy, PL
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (08) : 587 - 592
  • [3] The Role of Oral Beclometasone Dipropionate in the Treatment of Gastrointestinal Graft-versus-Host Disease
    Doan, Phuong L.
    Chao, Nelson J.
    DRUGS, 2009, 69 (10) : 1339 - 1350
  • [4] Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-Host Disease
    Martin, Paul J.
    Furlong, Terry
    Rowley, Scott D.
    Pergam, Steven A.
    Lloid, Michele
    Schubert, Mark M.
    Horgan, Kevin J.
    Storer, Barry E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (06) : 922 - 929
  • [5] Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host disease
    Inamoto, Yoshihiro
    Ito, Ayumu
    Nakashima, Toshihisa
    Usui, Asako
    Takeda, Wataru
    Tanaka, Takashi
    Kim, Sung-Won
    Kitano, Shigehisa
    Watanabe, Keisuke
    Kusaba, Kana
    Aruga, Yu
    Ikeda, Chiaki
    Kojima, Minoru
    Maezawa, Naoki
    Matsui, Hirotaka
    Hashimoto, Hironobu
    Ogawa, Chitose
    Fukuda, Takahiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
  • [6] The Use of Oral Beclomethasone Dipropionate in the Treatment of Gastrointestinal Graft-versus-host Disease: The Experience of the Fukuoka Blood and Marrow Transplantation (BMT) Group
    Takashima, Shuichiro
    Eto, Tetsuya
    Shiratsuchi, Motoaki
    Hidaka, Michihiro
    Mori, Yasuo
    Kato, Koji
    Kamezaki, Kenjiro
    Oku, Seido
    Henzan, Hideho
    Takase, Ken
    Matsushima, Takamitsu
    Takenaka, Katsuto
    Iwasaki, Hiromi
    Miyamoto, Toshihiro
    Akashi, Koichi
    Teshima, Takanori
    INTERNAL MEDICINE, 2014, 53 (12) : 1315 - 1320
  • [7] Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation
    McDonald, George B.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (10) : 1709 - 1724
  • [8] Oral Chronic Graft-Versus-Host Disease
    Dean, David
    Sroussi, Herve
    FRONTIERS IN ORAL HEALTH, 2022, 3
  • [9] Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease
    Elad, Sharon
    Zinchuk, Kevin
    Li, Shuli
    Cutler, Corey
    Liesveld, Jane
    Treister, Nathaniel S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (08) : 1748 - 1753
  • [10] Treatment of oral chronic graft-versus-host disease: a retrospective cohort study
    Ramos, Gabriela de Assis
    Boehmer Leite, Taisa Domingues
    Lobo, Camila Brandao
    da Silva Santos, Paulo Sergio
    Rodrigues Moreira, Maria Claudia
    Antunes, Heliton Spindola
    EINSTEIN-SAO PAULO, 2021, 19 : eAO6177